Journal Logo

Advanced Search

October 2022 - Volume 80 - Issue 4

  • George W. Booz, PhD, FAHA
  • 0160-2446
  • 1533-4023
  • 12 issues per year
  • Cardiac & Cardiovascular Systems 75/143, Pharmacology & Pharmacy 162/279
  • 3.271

​Cardiovascular complications of anti-cancer therapy: a developing storm in medicine (Alexander Burashnikov, Antonio Abbate, George W Booz). The current issue of the Journal of Cardiovascular Pharmacology presents up-to-date information on several aspects of cardio-oncology. Guha et al. review cardiometabolic consequences of anti-cancer therapy, an important emerging area in cardio-oncology. Cardiometabolic abnormalities, a major cause of morbidity and mortality in the general population, are likely to be significantly involved in a wide range of cancer drug-mediated CV toxicities. Two reviews deal with cancer therapy-induced cardiac arrhythmias, frequently encountered and with often serious complications. Essa et al. summarize the information on the occurrence and management of atrial and ventricular arrhythmias induced by chemotherapy. Burashnikov describes the available information on cancer drug-induced atrial fibrillation and underlying cellular mechanisms of this adverse effect.  Bannister et al. review cardiotoxicities caused by chemotherapeutic agents and their treatment, focusing on the left ventricular systolic dysfunction, the most commonly encountered cancer therapy-mediated cardiotoxicity. Artico et al. summarize the available information on the detection of cancer therapy-induced or -aggravated cardiac structural abnormalities by multiple imaging technologies. Timely detection of such abnormalities is critical for the management of the patients. Finally, Chuquin et al. address an important but poorly understood issue of the management of hypertension in cancer survivors. Hypertension is highly prevalent in cancer survivors, as a pre-existing disease, induced or aggravated by cancer therapy, or appearing de novo independent of cancer-related factors. Detection and proper treatment of hypertension in patients with cancer is vital for their morbidity and mortality. We trust our readers will find this series on cardio-oncology both informative and enjoyable. The lessons learned to date from this discipline have already had an impact on both medical practice and basic science.

JCVPEditor'sPick.png

 ​

Current Issue Highlights

Preprocedural Colchicine in Patients With Acute ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Randomized Controlled Trial (PodCAST-PCI)

Hosseini, Seyed Hossein; Talasaz, Azita H.; Alidoosti, Mohammad; More

Journal of Cardiovascular Pharmacology. 80(4):592-599, October 2022.

​2021 Twitter logo - blue.pnglinkedinlogo.png​

The editors of JCVP are calling for the submission of review articles dealing with all aspects of ER signaling in the heart, including the cGAS–cGAMP–STING pathway, mitochondria associated membranes, unfolded protein response (UPR), inflammasome activation, and ER stress. Articles with a therapeutic and disease-based perspective are welcomed. All articles will undergo peer review and appear in a regular issue in early 2023. Please contact the editorial office for additional information and prior approval for submission. ​​

The Journal of Cardiovascular Pharmacology announces an open call for a new review series dealing with the rapidly developing topic of RNA-based therapies. Reviews should focus on treating cardiovascular diseases or disorders, such as myocardial infarction, cardiac hypertrophy, cardiomyopathies, arrhythmias, valvular heart disease, aortic aneurysms, atherosclerosis and dysliidemia, and cerebrovascular disease. Various approaches, such as RNA aptamers, long non-coding RNAs, microRNAs, antisense nucleotides, and novel delivery strategies are included. The series is scheduled to appear early 2023. Please contact the editorial office for additional information and prior approval for submission.​​

View More Featured Jobs
Powered by: